Epithelium ; pathology ; Humans ; Melanoma ; pathology ; Skin Neoplasms ; pathology

Aged ; Esophageal Neoplasms ; pathology ; Esophagogastric Junction ; Humans ; Male ; Melanoma ; pathology

Adult ; Female ; Humans ; Melanoma ; diagnosis ; pathology ; Neurocutaneous Syndromes ; diagnosis ; pathology

Humans ; Melanoma ; pathology ; Meningeal Neoplasms ; pathology ; Neoplasm Recurrence, Local

Female ; Humans ; Melanoma ; pathology ; Uterine Cervical Neoplasms ; pathology

Humans ; Sarcoma, Clear Cell/pathology* ; Melanoma/pathology* ; Skin Neoplasms/pathology* ; Diagnostic Errors ; Soft Tissue Neoplasms ; Melanoma, Cutaneous Malignant

Humans ; Hyperplasia ; pathology ; Male ; Melanoma ; pathology ; Middle Aged ; Neoplasm Metastasis ; Palatine Tonsil ; pathology ; Skin Neoplasms ; pathology

Humans ; Intestine, Small ; pathology ; Male ; Melanoma ; diagnosis ; Middle Aged

Child ; Ear Auricle ; pathology ; Ear Neoplasms ; Humans ; Male ; Melanoma

Objective: To analyze the clinical features and prognosis of patients with cutaneous melanoma. Methods: The clinical data and follow-up data of 125 patients with cutaneous malignant melanoma (CMM) treated in the Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology between February 2008 and August 2019 were collected. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox proportional risk regression model was used for impact factor analysis. Results: Among the 125 patients, 12 were stage Ⅰ, 62 were stage Ⅱ, 30 were stage Ⅲ, and 21 were stage Ⅳ; 76 were acral and 49 were non-acral. The median survival time was 44 months, and the 1-, 2-, and 5-year survival rates were 85.4%, 63.2% and 38.7%, respectively. Kaplan-Meier univariate survival analysis showed that Karnofsky performance status score, tumor stage, primary site, vascular infiltration, Ki-67, BRAF, lactate dehydrogenase (LDH), and surgical treatment were related to the prognosis of patients (P<0.05). The median overall survival (OS) time of patients receiving interferon treatment was 53 months, which was better than 40 months of patients not receiving interferon treatment, but the difference was not statistically significant (P=0.448). Among stage Ⅲ patients, the median OS time of patients receiving interferon therapy was 40 months, which was better than 17 months of patients not receiving interferon therapy (P=0.012). Among stage Ⅱ patients, the 1-, 2-, and 5-year survival rates of acral patients were 97.1%, 84.7%, and 65.8%, and the 1-, 2-, and 5-year survival rates of non-acral patients were 93.3%, 70.0% and 17.0%. The prognosis of patients with stage Ⅱ acral type was better than that of non-acral type (P=0.043). The median survival time of stage Ⅲ patients with acral type was 32 months, better than 17 months of non-acral type, but the difference was not statistical significance (P=0.164). The median survival time of acral type and non-acral type was 8 months and 11 months respectively (P=0.458). Cox multivariate analysis showed that tumor stage and preoperative LDH level were independent prognostic risk factors for cutaneous melanoma. Conclusions: Interferon treatment can improve the prognosis of patients with stage Ⅲ, and stage Ⅱ acral type patients have better prognosis than that of non-acral type patients. Tumor stage and preoperative LDH level were independent prognostic risk factors for cutaneous melanoma.
Humans ; Melanoma/surgery* ; Skin Neoplasms/pathology* ; Prognosis ; Interferons ; Retrospective Studies